Jane Larae Liesveld, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Office: (585) 275-5823

Fax: (585) 273-1051

A member of the University of Rochester Medical Faculty Group

An Accountable Health Partner

Accepting New Patients

Locations

James P. Wilmot Cancer Center
601 Elmwood Ave
Rochester, NY 14642

Faculty Appointments

Professor - Department of Medicine , Hematology/Oncology (SMD)

Patient Care Setting

Cancer

Biography

While the doctor-patient relationship is one of potential intensity and privacy, the best patient care comes from teamwork, which values all who contribute to achieving high-quality care with compassion. Providing patients and their families with the knowledge and means to be partners in care is one of my key roles as a physician.

When a patient is diagnosed with a blood cancer or chronic blood condition, it is often the start of a new journey that will be the beginning of great change. Walking with patients through this journey from start to finish, and offering therapy and guidance along the way, is a source of professional and personal satisfaction for me. Hematology/oncology is a field where clinical and basic research can be rapidly applied to improve outcomes and quality of life.

I grew up in the Midwest, but have lived in Rochester since I began my post-doctoral medical training. My association with Strong, the University of Rochester and the people in our community and surrounding areas has enriched my life. I feel privileged to work in such a wonderful environment. I have expertise in novel therapies for acute myeloid leukemia, stem cell mobilization and homing, as well as stem cell transplantation.

Conditions I Treat

- Leukemia, all types
- Myeloproliferative disorders
- Myelodysplastic syndromes
- Multiple myeloma
- Stem cell transplantation

Research

Effects of oxygen metabolites/chemokines on hematopoietic stem cell expansion and preservation.

Effects of hematopoietic growth factors and inhibitors on AML blast proliferation (correlative clinical studies)

Effects of hematopoietic stem cell adhesion on marrow stromal cell cytokine production.

Role of signal transduction inhibition in treatment of acute myelogenous leukemia/myelodysplasia.

Characterization of mobilized peripheral blood stem cells

Credentials

Education

1980
MD | University Of Iowa Roy J & Lucille A Carver College Of Medicine

Post-doctoral Training & Residency

07/01/1988 - 06/30/1989
Fellowship in Research at University of Rochester Medical Center

07/01/1987 - 06/30/1988
Fellowship in Medical Oncology at University of Rochester Medical Center

07/01/1984 - 06/30/1987
Fellowship in Hematology at University of Rochester Medical Center

07/01/1981 - 06/30/1984
Residency in Internal Medicine at University of Rochester Medical Center

07/01/1980 - 06/30/1981
Internship in Internal Medicine at University of Rochester Medical Center

VIEW ALL

Awards

2009
Gilda's Club of Rochester Jacob Gitelman Award

2007
Hematology-Oncology Fellowship Teaching Award

2005 - 2007
Aplastic Anemia and MDS International Foundation Gordon Forgash Research Award

2004 - 2006
Lawrence A. Kohn Senior Teaching Fellowship
Sponsor: University of Rochester Department of Medicine

1998 - 2003
Leukemia Society of America, Clinical Scholar Award

1989 - 1992
Leukemia Society of America Special Fellowship

1989 - 1992
James P. Wilmot Postdoctoral Cancer Research Fellowship

1987 - 1988
American Cancer Society Clinical Fellowship Award

VIEW ALL

Clinical Trials

A Phase 1/2A, Open Label Dose Escalation and Expansion Study of Orally Administered CA-4948 as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Lead Researcher: Jane Larae Liesveld MD

This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with Acute Myelogenous Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). Patients enrolling in the Phase 1 portion of the study must meet one of the following criteria prior to consenting to the study: R/R AML with FLT3 mutations who have been previously treated with a FLT3 inhibitor R/R AML with spliceosome mutations of SF3B1 or U2AF1 R/R hrMDS with spliceosome mutations of SF3B1 or U2AF1 Number of pretreatments: 1 or 2 The Phase 2a Dose Expansion will be in 3 Cohorts of patients: R/R AML with FLT3 mutations who have been previously treated with a FLT3 inhibitor; R/R AML with spliceosome mutations of SF3B1 or U2AF1; and R/R hrMDS (IPSS-R score > 3.5) with spliceosome mutations of SF3B1 or U2AF1. All patients above have had ≤ 2 lines of prior systemic anticancer treatment. In previous versions of this protocol there was a Phase 1b portion of the study, in which patients with AML or hrMDS received CA-4948 in combination with venetoclax. This part of the study is no longer open for enrollment.

View Study Details

A Program for Monitoring Minimal Residual Disease Following Treatment of Patients With Acute Myeloid Leukemia or High Grade Myelodysplastic Syndrome

Lead Researcher: Jane Larae Liesveld MD

This study is being performed to develop assays to determine the impact of the therapy patients receive for treatment of AML or MDS and to determine if these tests can identify those patients who are at a greater risk for having their disease relapse.

View Study Details

Patents

Patent Title: Continuous Flow Chamber Device for Separation, Concentration and/or Purification of Cells
Patent #: 7,892,766
Issue Date: Feb 22, 2011
Country: United States
Invented By: Nichola Charles, Nathan Clark, John P Gentile, Michael R King, Jane Liesveld, Nipa Anand Mody

Publications

Journal Articles

12/13/2023
Locastro M, Mortaz Hedjri S, Wang Y, Mendler JH, Norton SA, Bernacki R, Carroll T, Klepin HD, Liesveld JL, Huselton EJ, Kluger B, Loh KP. "Telehealth Serious Illness Care Program for Older Adults with Hematologic Malignancies: A single-arm pilot study." Blood advances.. 2023 Dec 13; Epub 2023 Dec 13.

11/12/2023
Cliburn JA, Uy JC, Swift S, Liesveld JL, Iqbal MA, Jajosky AN, Becker MW. "Diagnosing familial platelet disorder with predisposition to myeloid malignancy: Lessons learned from a germline whole-gene deletion of RUNX1." International journal of laboratory hematology.. 2023 Nov 12; Epub 2023 Nov 12.

10/23/2023
Hill BT, Ma S, Zent CS, Baran AM, Wallace DS, Advani AS, Winter AM, Winter JN, Gordon LI, Karmali R, Liesveld JL, Mulford DA, Rowland C, Bui A, Sportelli P, Miskin HP, Weiss MS, Friedberg JW, Barr PM. "Response-Adapted, Time-Limited Venetoclax, Umbralisib and Ublituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia." Blood advances.. 2023 Oct 23; Epub 2023 Oct 23.

Books & Chapters

2017
Chapter Title: Stem Cell Mobilization
Book Title: In: Encyclopedia of Cancer
Author List: Liesveld, JL
Edited By: Schwab, M
Published By: Springer-Verlag 2017

2016
Chapter Title: Acute Myelogenous Leukemia
Book Title: In: Williams Hematology
Author List: Liesveld, JL and Lichtman, MA
Edited By: Kaushansky K, Lichtman MA, Prchal JT, Levi MM, Press OW, Burns LJ, Caligiuri MA
Published By: McGraw Hill 2016 in New York, NY

2016
Chapter Title: Chronic Myelogenous Leukemia and Related Disorders
Book Title: In: Williams Hematology
Author List: Liesveld, JL and Lichtman, MA
Edited By: Kaushansky K, Lichtman MA, Prchal JT, Levi MM, Press OW, Burns LJ, Caligiuri MA,
Published By: McGraw Hill 2016 in New York, NY

VIEW ALL PUBLICATIONS

Videos

SECOND OPINION | Leukemia (CLL) | APT

SECOND OPINION | Leukemia (CLL) | APT | Full Episode

Reviews

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information.